RMD.AX - ResMed Inc.

ASX - ASX Delayed Price. Currency in AUD
16.31
+0.01 (+0.06%)
At close: 4:10PM AEST
Stock chart is not supported by your current browser
Previous Close16.30
Open16.39
Bid16.32 x 0
Ask16.32 x 0
Day's Range16.29 - 16.48
52 Week Range12.65 - 16.57
Volume1,238,816
Avg. Volume1,565,835
Market Cap22.721B
Beta (3Y Monthly)0.72
PE Ratio (TTM)52.80
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.18 (1.28%)
Ex-Dividend Date2018-05-09
1y Target EstN/A
  • Markit16 days ago

    See what the IHS Markit Score report has to say about ResMed Inc.

    ResMed Inc NYSE:RMDView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for RMD with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.07 billion over the last one-month into ETFs that hold RMD are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents17 days ago

    Edited Transcript of RMD earnings conference call or presentation 2-May-19 8:30pm GMT

    Q3 2019 Resmed Inc Earnings Call

  • ResMed's Revenue Growth Accelerates
    Motley Fool17 days ago

    ResMed's Revenue Growth Accelerates

    The medical-device maker continues to roll out new products and grab market share.

  • Resmed Inc (RMD) Q3 2019 Earnings Call Transcript
    Motley Fool20 days ago

    Resmed Inc (RMD) Q3 2019 Earnings Call Transcript

    RMD earnings call for the period ending March 31, 2019.

  • Associated Press21 days ago

    ResMed: Fiscal 3Q Earnings Snapshot

    The San Diego-based company said it had net income of 73 cents per share. Earnings, adjusted for amortization costs and pretax expenses, came to 89 cents per share. The results exceeded Wall Street expectations. ...

  • Motley Fool22 days ago

    Did David Stick His Neck Out Too Far With This 5-Stock Sampler?

    It’s time for the one-year update on a set of stocks that David Gardner picked to commemorate April the giraffe giving birth live on YouTube.

  • Were Hedge Funds Right About Souring On ResMed Inc. (RMD)?
    Insider Monkey2 months ago

    Were Hedge Funds Right About Souring On ResMed Inc. (RMD)?

    Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]

  • Reuters3 months ago

    Fisher & Paykel, ResMed settle global patent disputes; shares jump

    New Zealand medical device maker Fisher & Paykel Healthcare Corp Ltd and U.S. rival ResMed Inc have agreed to settle patent infringement disputes, ending a three-year tussle that spanned the globe and cost each side millions of dollars in legal fees. In a joint statement on Thursday, the companies agreed to end all ongoing infringement cases and said neither would admit liability or make any payment. Fisher & Paykel shares were 6.9 percent higher after the announcement, reaching a more than four-month peak, whereas ResMed's Australian depository receipts were 1.1 percent firmer.

  • Reuters3 months ago

    NZ's Fisher & Paykel and ResMed settle global patent disputes

    Medical device maker Fisher & Paykel Healthcare and U.S.-based ResMed on Thursday agreed to settle disputes over patent infringement, bringing to an end a tussle spanning the globe. The two companies had ...

  • ResMed (RMD) Q2 2019 Earnings Conference Call Transcript
    Motley Fool4 months ago

    ResMed (RMD) Q2 2019 Earnings Conference Call Transcript

    RMD earnings call for the period ending December 31, 2018.

  • GuruFocus.com4 months ago

    3 Stocks Move Friday

    ResMed, Intuitive Surgical fall, OSI Systems rises

  • Associated Press4 months ago

    Western Digital, Starbucks rise while AbbVie, Intel drop

    Stocks that moved substantially or traded heavily Friday: Western Digital Corp., up $3.02 to $43.16 The hard-drive maker reported better-than-expected quarterly financial results and an upbeat forecast. ...

  • TheStreet.com4 months ago

    ResMed Tanks on Second-Quarter Revenue Miss

    The San Diego company reported a 9% increase in adjusted revenue to $651.1 million but lagged Wall Street's expectations of $667 million. "We had a solid quarter with top-line growth and gross margin expansion, as well as continued fiscal discipline to drive leverage and improved operating profit," said Mick Farrell, ResMed's CEO. Through the first half of the company's fiscal year, ResMed has posted an increase of 11% on adjusted revenue while earnings have gained 9%.

  • Acquisitions Cause ResMed's Profit Growth to Stall
    Motley Fool4 months ago

    Acquisitions Cause ResMed's Profit Growth to Stall

    Lavish spending on additions to the company's growing software business took a toll on net income.

  • Why ResMed Is Plunging Today
    Motley Fool4 months ago

    Why ResMed Is Plunging Today

    Disappointing quarterly results took a toll on the medical-device stock.

  • CNBC4 months ago

    Stocks making moves midday: Airlines, Ford, Western Digital, Vale & more

    These are the companies making headlines in the middle of Friday trading:Intel INTC , AMD AMD – Intel fell 5.5 percent after the chipmaker said it expects revenue to be nearly flat compared to last year.

  • Dow Jones Futures Pare Gains On Mueller Probe Arrest; Intel Leads 5 Top Stocks Moving
    Investor's Business Daily4 months ago

    Dow Jones Futures Pare Gains On Mueller Probe Arrest; Intel Leads 5 Top Stocks Moving

    Stone futures rose but pared gains on news that Trump adviser Roger Stone had been arrested. Intel fell on guidance. Starbucks rose on strong earnings.

  • Highly Rated Medtech Stock Topples On Mixed Earnings Report
    Investor's Business Daily4 months ago

    Highly Rated Medtech Stock Topples On Mixed Earnings Report

    ResMed stock crashed Thursday after the medical technology firm missed quarterly sales projections by $16 million. ResMed stock closed up a fraction.

  • Associated Press4 months ago

    ResMed: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had net income of 86 cents. Earnings, adjusted for amortization costs and costs related to mergers and acquisitions, came to $1 per share. The ...

  • GuruFocus.com4 months ago

    5 Companies Hit 52-Week Highs

    As of late, multiple companies have managed to reach yearly highs

  • 3 Healthcare Stocks Hitting 52-Week Highs: Are They Buys?
    Motley Fool4 months ago

    3 Healthcare Stocks Hitting 52-Week Highs: Are They Buys?

    Can the sizzling momentum continue for these high-flying healthcare stocks?